Page 2 - Oncomap Extra News Today

Exact Sciences (NASDAQ:EXAS – Get Rating) and Viridian Therapeutics (NASDAQ:VRDN – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Insider and Institutional Ownership 94.5% of Exact Sciences shares are […]

Viridian Therapeutics (NASDAQ:VRDN – Get Rating) and Exact Sciences (NASDAQ:EXAS – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Volatility & Risk Viridian Therapeutics has a beta of 1.13, […]

Exact Sciences (NASDAQ:EXAS – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Saturday. Several other equities research analysts have also recently weighed in on EXAS. The Goldman Sachs Group dropped their price target on shares of Exact Sciences from $100.00 to $85.00 and […]

Exact Sciences (NASDAQ:EXAS – Get Rating) and Genetron (NASDAQ:GTH – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Institutional and Insider Ownership 94.5% of Exact Sciences shares are held […]

Exact Sciences (NASDAQ:EXAS – Get Rating) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday. Several other equities analysts have also recently weighed in on the company. Raymond James decreased their price objective on Exact Sciences from $90.00 to $80.00 in a report on Wednesday, April […]

PotNetwork (OTCMKTS:POTN – Get Rating) and Exact Sciences (NASDAQ:EXAS – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership. Analyst Ratings This is a summary of current ratings and target […]

Equities analysts forecast that Exact Sciences Co. (NASDAQ:EXAS – Get Rating) will report sales of $498.48 million for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Exact Sciences’ earnings, with the lowest sales estimate coming in at $492.40 million and the highest estimate coming in at $505.50 million. Exact […]

/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and...

/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and...

MDxHealth (NASDAQ:MDXH – Get Rating) and Exact Sciences (NASDAQ:EXAS – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings. Profitability This table compares MDxHealth and Exact Sciences’ net margins, return […]